U nlocking the information contained within the human genome will likely advance our understanding of cardiovascular (CV) health and disease by leading to discovery of new molecules, pathways, and networks. A central strategy in genetic studies of CV disease has been to correlate human genomic DNA variation with clinical phenotypes, such as myocardial infarction, heart failure, stroke, and their risk factors, with a range of experimental designs and analytical procedures. The ability to detect genomic differences between individuals is the foundation of this research. Human genomic variation exists in many forms, each of which has unique qualitative and quantitative features. Each form of human genomic variation is composed of many individual variants that occur across the genome. The population frequency of individual variants can range from rare to common. The effect of a specific genomic variant can range from beneficial to neutral to deleterious. To rapidly translate genomic knowledge into diagnosis and treatment of CV disease, it is logical to search for common genomic variants that have a non-neutral impact. In the recent past, one form of genomic variation, the single-nucleotide variant, has dominated the experimental landscape: It is the currency of present genetic CV disease studies. However, recent developments indicate that the focus on single-nucleotide polymorphisms (SNPs) alone will not capture the full range of meaningful human genomic variation, such as a newly characterized and annotated form called copy number variation (CNV).
U nlocking the information contained within the human genome will likely advance our understanding of cardiovascular (CV) health and disease by leading to discovery of new molecules, pathways, and networks. A central strategy in genetic studies of CV disease has been to correlate human genomic DNA variation with clinical phenotypes, such as myocardial infarction, heart failure, stroke, and their risk factors, with a range of experimental designs and analytical procedures. The ability to detect genomic differences between individuals is the foundation of this research. Human genomic variation exists in many forms, each of which has unique qualitative and quantitative features. Each form of human genomic variation is composed of many individual variants that occur across the genome. The population frequency of individual variants can range from rare to common. The effect of a specific genomic variant can range from beneficial to neutral to deleterious. To rapidly translate genomic knowledge into diagnosis and treatment of CV disease, it is logical to search for common genomic variants that have a non-neutral impact. In the recent past, one form of genomic variation, the single-nucleotide variant, has dominated the experimental landscape: It is the currency of present genetic CV disease studies. However, recent developments indicate that the focus on single-nucleotide polymorphisms (SNPs) alone will not capture the full range of meaningful human genomic variation, such as a newly characterized and annotated form called copy number variation (CNV).
Main Varieties of Human Genomic Variation
The main forms of human genomic variation are shown in Figure 1 . These include SNPs, which are qualitative in nature and involve only a single nucleotide, and a family of genomic changes collectively called structural variations, which are quantitative in nature because they affect the dosage or copy number of a particular genomic region. Structural variant types include deletions, duplications, inversions, and rearrangements of "chunks" of the genome, which range from small insertions and deletions that involve 1 to 50 base pairs through to very large cytogenetic changes that involve entire chromosomes. It is estimated that roughly 5% of the human genome is structurally variable. 1 The recently characterized CNVs comprise structural variants of intermediate size that range from 1000 to 5ϫ10 6 bases of DNA. Furthermore, the types of CNV changes (ie, deletions, duplications, and inversions) are analogous to large cytogenetic changes that were previously visualized through microscopy.
Other variable regions include short repetitive sequences, 1 to 5 base pairs in length, termed short tandem repeat sequences or microsatellite repeats, such as (A)n, (CA)n, or (AAG)n, where n is variable. These repeat units, being neutral and widely dispersed, have been used as markers to "tag" segments of the genome that can then be tracked through families in linkage studies. A few short tandem repeats are functional and give rise to human diseases [eg, neurological disorders resulting from expansion of (CAG)n repeats]. 2 Minisatellites or "variable number tandem repeats," which are 5 to 64 base pairs in length and extend over several thousand base pairs, are less evenly distributed but highly informative. 2 Transposons and transposon-like repetitive elements, such as the ubiquitous Ϸ300 -base pair Alu repeat sequence, also contribute to human genomic variation. 3 Whereas this review will focus on the relationship of SNPs and CNVs to the CV system, a more detailed description of all forms of human genomic variation, such as tandem repeats and various interspersed genomic elements, can be found in a recent comprehensive review. 1
Mutations Versus Polymorphisms
When genomic variants are discussed, both "mutation" and "polymorphism" are used, sometimes interchangeably. By convention in human genetic research, any genomic variant with population frequency Ͻ1% is termed a "mutation," whereas a variant with population frequency Ͼ1% is termed a "polymorphism," 4 a convention that will be followed in this review. The distinction is based on population frequency of the variant rather than the type of variant or its possible functional impact. However, as a rule, rare mutations tend to have a functional impact that deviates from the "wild type" (or most common form), yielding a higher signal-to-noise ratio for detection of a genetic influence on a trait. In contrast, polymorphisms tend to connote less functionally deviant genomic variants. However, some rare genomic mutations have been found to be functionally neutral, whereas some common polymorphisms also have a major functional impact.
Technologies to Visualize Human Genomic Mutations
Technology is an important determinant of the type of genomic mutation detected. For instance, in the pre-polymerase chain reaction (PCR) era (the 1970s and early 1980s) the most prevalent mutation types in disease databases were large-scale genomic DNA changes, such as large insertions and deletions. One reason for this was that most genomic mutations in this era were detected by the Southern blot method. Southern blots were ideal for detection of large-scale rearrangements that involved Ͼ200 bases of target genomic DNA, which was the method's resolution limit. However, detection of small mutations was beyond the Southern blot's resolving capacity, unless a mutation altered a recognition site for a restriction endonuclease. Another key methodology to pinpoint variants involved cloning of human genomic DNA coupled with manual DNA sequence analysis, a combination of technologies that were comparatively inefficient and required high levels of skill, labor, and exposure to radioactivity. These now almost forgotten methods were superseded in the 1980s by PCR and automated DNA sequence analysis. With the invention of PCR, it became possible to rapidly amplify discrete regions of genomic DNA (up to 2000 base pairs) in sufficient quantity and with sufficient quality to allow for high-capacity, high-resolution automated DNA sequence analysis, which in turn enabled rapid ordering of the 4 letters of the genomic alphabet (A, C, G, T) into a continuous data string. Since the late 1980s, the complementary fundamental technologies of gene amplification by PCR and automated genomic DNA sequencing, together with advances in DNA cloning, drove genomic research and ultimately enabled the determination of the entire sequence of the human genome. 5, 6 These methods were ideally suited to detect small qualitative changes in the genomic sequence of an individual: 1 or a few genomic DNA nucleotide bases.
SNPs in the Human Genome
The result of the domination of these methods in human genetic research has been that most genomic variation detected over the past 20 years has been small and qualitativemainly single-nucleotide changes. Their potential pathogenicity is summarized in Figure 2 . The 2001 draft of the human genome sequence provided, in effect, an initial but imperfect reference standard for subsequent annotation of genomic variation. Every examination of partial or complete genomic DNA sequence since then has essentially been a "resequencing" experiment that has built on the first draft. The cumulative results of automated DNA sequence analysis over the past 6 years have helped identify millions of common differences between people at the level of single letters of DNA code. These differences, called SNPs, occur with a frequency of Ϸ1 of every 400 bases of DNA sequence. The extent of SNP variation in populations was exquisitely defined by the International HapMap project 7 : If one considers only SNPs that are present in Ͼ5% of specific population samples, SNPs may involve up to 10 million nucleotide bases of DNA, or Ϸ0.3% of the total genome. Once SNPs have been defined, various dedicated technologies to assay individual nucleotides can be used to screen human samples. A popular current platform is the high-density SNP microarray, which permits simultaneous assay of Ͼ500 000 and soon Ͼ1 000 000 SNPs from a human genomic DNA sample.
Until recently, SNPs were considered to be the major source of genomic variation in the phenotypic differences between people, which include physiologically neutral features like eye color as well as medically relevant phenotypes such as disease susceptibility and differential response to medications. However, individuals with a hammer seem to see nails everywhere; by analogy, investigators with technologies designed to assess single nucleotides soon regard these as the principal form of genetic variability. The publication of SNP-based studies that attempt to identify the genetic basis of disease traits has become commonplace in the CV field. As important as current SNP-based methods are, however, it is important to recall that large-scale, cytogenetic, chromosomal changes rather than single-nucleotide variants have long been recognized to cause certain CV disorders, even before recent developments that culminated in publication of the CNV map of the human genome.
Historical Snapshot: CV Disorders Caused by Cytogenetic Chromosomal Changes
Since the 1960s, traditional microscopy-based karyotype analysis and, more recently, higher-resolution fluorescent dye-based visualization with microscopy would occasionally detect patients whose nuclei harbored large-scale rearrangements that affected whole chromosomes or sizable fragments of chromosomes. The changes that were cytogenetically visible included deletion (loss of one or both copies), duplication (gain of one or more copies), inversion (flipped orientation of a chromosomal segment), and translocation (transfer of a piece of one chromosome to another). A single instance of such a dramatic chromosomal rearrangement would encompass millions to hundreds of millions of DNA nucleotides. The major types of chromosomal alterations are shown in Figure 3 . These major rearrangements were considered to be rare events and were frequently associated with clinical syndromes: The most familiar example would be the duplication of one copy of chromosome 21 entirely or in part, which is known as Down syndrome. Several disorders that result from large cytogenetic changes involved the CV system and some of these are listed in Table 1 . 9 -18 At the same time, some dramatic, large-scale, cytogenetic variants were detected incidentally without apparent clinical impact. 19 The standard method for detection of large-scale chromosomal variants has been GTG-banded karyotyping, which has a resolution of 3 to 5 Mb. Finer-resolution methods, collectively called fluorescent in situ hybridization (FISH), are based on hybridization of fluorescent probes onto chromosomes that have been captured in metaphase or interphase. Interestingly, improvements in cytogenetic technology have allowed for detection of smaller structural variants (or CNVs) approached from the low-resolution side of the methodology spectrum, whereas microarray-based platforms have permitted the detection of structural changes from the higher-resolution side of the spectrum. The net result has been that a growing number of common, smaller, quantitative genomic variants are being independently discovered by various technologies. In contrast to the large, uncommon, and frequently pathogenic cytogenetic changes, the much smaller-sized CNVs appeared to be prevalent in the healthy control population. Some genetics researchers clearly foresaw that these genomic structural variants would be a ubiquitous source of variation and likely The type of genomic alterations of the normal structure that lead to deletion, duplication, and inversion are shown at the top. Segment B represents the normal structure of a chromosomal locus that contains a cluster of 3 genes (1, 2, and 3). Segment C shows the detailed structure of gene 2 and includes key functional elements, such as the 5Ј regulatory region, with promoter, enhancer, and silencer elements; the 3Ј untranslated regions that can regulate message stability; and the intron-exon structure of the gene. Any of these structural and functional elements can become involved in a CNV, with a range of functional consequences that depends on the size and nature of the variant and the affected functional domains. Adapted from Hegele 8 Table 2 .
Brief Overview of New Genomic Technologies
With variation characterized at the single-nucleotide level and also the microscopic level, present-day strategies and tools now examine the variation between these 2 extremes: examination of submicroscopic structural variants on the scale of Ϸ1 kb to 3 Mb (Table 2) . When screening is performed on a genome-wide scale, the main approach is array-based analysis, which was used in the first studies that described the global presence and distribution of CNVs in the human genome. 22, 23 The driving force behind this breakthrough technology was the development of microarrays. 24 Composed of thousands of microscopic DNA probes spotted onto a solid surface such as a glass slide, microarrays allow for much greater resolution. In array-based comparative genome hybridization, the whole genome is fragmented, labeled, and then competitively hybridized to arrays spotted with one of several DNA sources, such as BACs (clone based) or PCR fragments. 25, 26 Representational oligonucleotide microarray analysis, is a variation of array-based comparative genome hybridization. It includes an additional preparative step to reduce the complexity of the input DNA. 27 High-density SNP arrays can also be used, such as those used in the development of the most recent CNV map of the human genome. 28 In the future, it is likely that with the possible development of inexpensive and reliable whole-genome sequencing, computational approaches (eg, sequence-assembly comparison) will become the most popular choice for identification of structural variants. Here, the advantage is that all types of variants, such as balanced inversions, can be easily detected, and the resolution will be down to the nucleotide level. A recent in silico strategy mapped over 1.1 million paired-end sequences from a high-density fosmid library against a reference assembly and discovered numerous CNVs that had not been identified previously, the majority below the expected resolution of other array platforms. 29 Also, SNP genotypes that are obtained from high-density microarrays will need to be further assessed for the possibility that they overlap with CNVs. This could be resolved bioinformatically or perhaps will require a complete overhaul of high-density SNP microarray design.
Newer methods have also been developed to detect structural changes in targeted regions in a more cost-effective and higher-throughput fashion than the traditional fluorescent in situ hybridization (FISH) and Southern blot methods. Such alternative methods include quantitative multiplex PCR of short fluorescent fragments, 30 multiplex amplifiable probe hybridization, 31, 32 and multiplex ligation-dependent probe amplification. 33, 34 Such methods allow for the scoring of up to 50 independent regions in one experiment and can detect deletions or insertions that involve whole exons that would otherwise be overlooked by traditional exon-by-exon sequence analysis.
CNVs in the Human Genome
The meteoric ascent of CNVs into contemporary genetic discourse began with 2 seminal 2004 publications. 22, 23 Each research effort used distinct but complementary technologies designed to detect dosage differences of genes and chromosomal regions compared with the standard 2 copies (maternal and paternal) that are expected in each genome. Both teams saw numerous submicroscopic chromosomal alterations in the genomes of small samples of healthy control subjects. These quantitative genomic variants, eventually called CNVs, were analogous to the chromosomal changes detected by classical cytogenetic methods described above. Initially, larger variants were found, which ranged between 10 kb and 500 kb in size and numbered in the tens to hundreds per 
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Copy Number Variation and Cardiovascular Diseasegenome. 22, 23 Recently, much smaller variants, mainly deletions that ranged from 500 bp to 10 kb in size have been found; they number in the hundreds and perhaps the thousands in the genome. 35, 36 CNVs can also include variants that primarily affect qualitative genomic attributes of large chromosomal segments, such as through inversion of genomic regions with no change in copy number per se. The potential mechanisms that underlie the generation of CNVs may have broader implications as a source of variation between species and a means to generate new genes with new functions. 37 Surprising features of CNVs included their ubiquity in the genome, high population frequency, and frequent lack of association with disease phenotypes. The genomes of any 2 individuals might differ from each other by hundreds to thousands of CNV events. This high prevalence in the genomes of apparently healthy individuals motivated efforts to create a unified CNV map in control samples and to integrate these with SNP maps by study of samples that had already been mapped for SNPs. In late 2006, Redon and colleagues published the CNV map of the genome, 28 followed by a similar map published by Wong and colleagues in early 2007. 38 Redon and colleagues defined a CNV to encompass any submicroscopic chromosomal change that affected Ͼ1000 (and up to half a million or more) nucleotides of genomic DNA. These authors used both SNP microarrays and comparative hybridization to identify a total of 1447 CNVs in the genomes of 270 healthy individuals from 4 different geographical ancestries. 28 The extent of the variation was breathtaking: These relatively common CNVs cumulatively affected 360 million nucleotides, or Ϸ12% of the human genome (one of a homologous pair of chromosomes was often 1 million nucleotides and 20 genes shorter than the other). The map subsequently generated by Wong and colleagues 38 was based on study of the genomes of 105 individuals with the use of a whole-genome comparative hybridization assay and reported Ϸ800 CNVs that had a frequency of Ͼ3%; about two thirds of these CNVs overlapped with known genes.
How Do CNVs Cause Disease or Influence Phenotypes?
CNVs can affect phenotypes by alteration of levels of genes and gene products both at the level of transcription of genomic DNA to the RNA message and presumably at translation of the RNA message to the protein product. 4 For instance, deletion of one copy of a dosage-sensitive gene results in deficient function that cannot be rescued. Also, genomic deletions in apparently normal individuals might not directly cause a simple monogenic disease, but in the presence of additional genetic or environmental factors may contribute to development of complex polygenic CV diseases with late onset. Similarly, gene-dosage increases are already known to cause a few diseases in humans, but the ubiquity of CNVs means this could be a much more important and general disease mechanism. Furthermore, CNVs may have a role in common diseases if only for the simple reason that certain CNVs span regions that contain many genes. Therefore, the study of SNPs alone when genomic variation is correlated with disease is now inadequate in the context of knowledge of CNVs. A focus on SNPs will literally "miss the forest for the trees." For instance, we recently showed that testing for both SNPs and CNVs expands the molecular diagnosis of familial hypercholesterolemia. 39 Like SNPs, smaller CNVs will affect only single genes and thus contribute, together with SNPs, to single-gene disorders. However, unlike SNPs, larger CNVs can affect 2 or more contiguous genes and thus contribute to syndromic or complex disorders caused by defects in multiple genes. Finally, some CNVs involve gene-poor regions and may either be functionally neutral or may still have an impact on disease susceptibility through their effects on nontranscribed domains that regulate gene expression at a distance. 4 Like any genetic variant, any deleterious effect must be considered in the context of redundancy of other related genes and gene products that might rescue a deficiency that results from the CNV.
An estimation of the relative impact of SNPs and CNVs on gene expression phenotypes was recently reported by Stranger and collegues. 40 With the use of lymphoblastoid cell lines of all 210 unrelated individuals from the International HapMap project, association analyses compared the expression levels of Ϸ14 000 genes with SNPs and CNVs. Of the 1061 genes found to be associated, 83.6% were associated with SNPs, 17.7% were associated with comparative genome hybridization clones, and only 1.3% were associated with both types of genetic variation, which clearly indicated that exploration of only one source of variation may not be enough to explore the genetic causes of disease. Table 3 shows a list of selected CV diseases, each of which has an established and strong genetic component, often single-gene or "monogenic" mendelian disorders, for which CNVs overlap the chromosomal region that harbors the disease gene. 28 These represent Ϸ7% of the total of Ϸ300 disease genes that are contained within CNVs from the map by Redon and colleagues. Most CNVs that overlap with CV monogenic disorders are present at a frequency between 1% and 5%, which seems reasonable when the fact that these disorders are rare in the general population is considered. One exception that shows a high degree of common variability is LPA: The region that harbors LPA on chromosome 6 was remarkably variable and commonly polymorphic in both the Redon and Wong CNV maps. 28, 38 The findings are consistent with the known biology of LPA, which encodes the atherogenic apolipoprotein(a). This protein has long been known to have marked size heterogeneity as a result of variability in the number of tandem repeats of genomic DNA sequence that encodes a critical expressed functional domain. With regard to other genes in Table 3 , the original study samples were relatively small, so it remains important to replicate these findings in larger independent samples to demonstrate that these diseases are associated with CNVs. If replicated, it may be worthwhile to consider these CNVs in studies of association or linkage with specific CV disease traits. If these variants actually occur with such frequency in the general Replicated refers to a positive finding from both methods used in Redon et al. 28 CHD indicates coronary heart disease; AR, autosomal recessive; AD, autosomal dominant; CD, complex disease; XLR, X-linked recessive; KO, knockout; MI, myocardial infarction; CHF, congestive heart failure; TG, transgenic; and OMIM, reference number in Online Mendelian Inheritance in Man database.
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population, then perhaps subtle or later-onset forms of the monogenic phenotypes might be more prevalent than has been generally recognized.
Curbing Enthusiasm: Time Needed to Characterize, Validate, and Associate
Although completion of genome-wide CNV maps has been a great accomplishment, it is important to recognize certain limitations. For instance, genomic DNA from cell cultures was used almost exclusively, which, although it provided numerous practical advantages, has the potential limitation that cells in culture might more readily acquire genomic CNVs that were not present in the starting material. Expansion of the databases to contain CNV information from multiple platforms on thousands of individuals analyzed according to established standards is essential if CNV mapping is to become a more routinely used technology in research and diagnosis.
On the assumption that technical issues are dealt with, assay performance is optimized, and consensus standards are applied to CNV mapping, the next logical step would be to determine the potential role of CNVs in rare or common diseases. Large-scale genome-wide association and casecontrol studies will have to incorporate CNV analyses into their designs. Future comprehensive studies of CV disease will require reliable, complementary, and harmonized technologies that account for several forms of genomic variation simultaneously. For any particular CNV, increased confidence of its validity would derive from confirmation of the same CNV in the same individual by different technologies and from observation of the same CNV in multiple individuals by multiple methodologies.
Because CNVs are so prevalent and because certain chromosomal regions that harbor CNVs recur across multiple normal samples, it is important to curb the inclination to provide clinical advice on the basis of the presence of CNVs until CNVs have been even more completely mapped in a much wider range of normal healthy subjects, and their association with phenotypes, particularly congenital syndromes, single-gene disorders, and complex diseases of later life, has been more fully characterized.
Implications of CNV Knowledge to Cardiovascular Health and Disease
There is considerable excitement in the recognition of the research opportunities created by awareness of CNVs as an entire new family of genomic DNA variants. In the clinical arena, will the benefits of new technologies with improved resolution be offset by problems that arise from the detection of large numbers of heretofore-unseen genomic abnormalities? The probability of finding normal genomic variants in screened samples is now markedly increased, given the sensitivity of the new methods and the ubiquity of CNVs Ͼ1 kb in the human genome. In a clinical research setting, how will the management and counseling of a patient and his/her family unfold with and without taking CNVs into account? Will ethical issues that arise from analysis of CNVs simply mirror past issues encountered when cytogenetic methods are used? Could past medical genetic diagnosis be revised in light of new knowledge afforded by CNVs? Should archived specimens be reevaluated in light of the CNV map? These questions and others 41 will require attention soon.
Past clinical experience with cytogenetic abnormalities may provide important direction for new CNV information. For instance, in postnatal diagnosis of a child with a CV developmental or morphological abnormality, it has been generally accepted that any genomic CNV inherited from a phenotypically normal parent is probably less clinically significant than a variant that has arisen de novo. 42 When a CNV has been detected in the genome of a child with a clinical abnormality, it would thus be essential to exclude a de novo chromosomal change in the parents, only after nonpaternity is excluded. The same CNV in a healthy parent suggests it might be a normal variant. If the CNV is not present in either parent, it could then be searched against the database of known CNVs; potential pathogenicity could be inferred through homology of the CNV with known nondisease-related CNVs. However, creation of an extensive and authoritative archive that relates CNVs to disease will require time, resources, and cooperation between research and clinical communities. A current Web site that contains integrated data and includes CNVs is found at http://projects.tcag.ca/variation.
Conclusions
Thus, the CNV maps in healthy "normal" individuals add a new dimension to the study of the human genome. These new comprehensive genomic maps and analyses have initiated a paradigm shift that might profoundly affect CV biology and medicine. They have altered the notion that SNPs are the main source of interindividual genomic variation. The size and ubiquity of CNVs suggest a potential role for susceptibility to common complex, polygenic CV diseases. Although it is promising as a hypothesis for human genetic research, the ultimate proof of the involvement of CNVs in CV disease phenotypes will require large-scale studies that comprise well-phenotyped cohorts and comprehensive, robust methods to classify individuals according to their CNV status. In any event, future genomic mapping experiments and genomewide association analyses, and their respective detection technologies, will need to account for the presence of CNVs. Current platforms to study the genome may need to be redesigned either to optimize detection of CNVs or minimize their interference with detection of other forms of genomic variation. As the "personal genome" moves closer to reality, it will be important to interpret the biological meaning of all forms of genomic variation (SNPs and CNVs) for any individual. Finally, CNVs are now part of the contemporary discourse on genomic variation studies and their biological, health, and societal implications. More research is required to fully understand the implications and potential applications of human genomic CNVs.
